These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15880742)

  • 21. The mGlu5 receptor agonist CHPG stimulates striatal glutamate release: possible involvement of A2A receptors.
    Pintor A; Pèzzola A; Reggio R; Quarta D; Popoli P
    Neuroreport; 2000 Nov; 11(16):3611-4. PubMed ID: 11095529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
    Jiménez A; Bonastre M; Aguilar E; Marin C
    Psychopharmacology (Berl); 2009 Oct; 206(2):233-42. PubMed ID: 19636538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mGlu5R promotes glutamate AMPA receptor phosphorylation via activation of PKA/DARPP-32 signaling in striatopallidal medium spiny neurons.
    Dell'anno MT; Pallottino S; Fisone G
    Neuropharmacology; 2013 Mar; 66():179-86. PubMed ID: 22507666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamus.
    Salt TE; Binns KE; Turner JP; Gasparini F; Kuhn R
    Br J Pharmacol; 1999 Jul; 127(5):1057-9. PubMed ID: 10455248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Nash JE; Brotchie JM
    Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism.
    O'Leary DM; Movsesyan V; Vicini S; Faden AI
    Br J Pharmacol; 2000 Dec; 131(7):1429-37. PubMed ID: 11090117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats.
    Spooren WP; Gasparini F; Bergmann R; Kuhn R
    Eur J Pharmacol; 2000 Oct; 406(3):403-10. PubMed ID: 11040347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
    Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
    Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The metabotropic glutamate mGluR5 receptor agonist CHPG stimulates food intake.
    Ploj K; Albery-Larsdotter S; Arlbrandt S; Kjaer MB; Skantze PM; Storlien LH
    Neuroreport; 2010 Jul; 21(10):704-8. PubMed ID: 20505551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
    Turle-Lorenzo N; Breysse N; Baunez C; Amalric M
    Psychopharmacology (Berl); 2005 Apr; 179(1):117-27. PubMed ID: 15726332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
    Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
    Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
    Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.
    Marti M; Paganini F; Stocchi S; Mela F; Beani L; Bianchi C; Morari M
    J Neurochem; 2003 Feb; 84(4):792-802. PubMed ID: 12562523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor.
    Movsesyan VA; Stoica BA; Faden AI
    J Neurochem; 2004 Jun; 89(6):1528-36. PubMed ID: 15189356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
    Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.